US20160195522A1 - Method of agglutination immunoassay - Google Patents

Method of agglutination immunoassay Download PDF

Info

Publication number
US20160195522A1
US20160195522A1 US14/894,207 US201414894207A US2016195522A1 US 20160195522 A1 US20160195522 A1 US 20160195522A1 US 201414894207 A US201414894207 A US 201414894207A US 2016195522 A1 US2016195522 A1 US 2016195522A1
Authority
US
United States
Prior art keywords
variation
intensity
absorbance
scattered light
determined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/894,207
Other languages
English (en)
Inventor
Hiroshi Takahashi
Tadaaki Yoshida
Yoshimasa Banba
Yuki Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sekisui Medical Co Ltd
Original Assignee
Sekisui Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51988979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160195522(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sekisui Medical Co Ltd filed Critical Sekisui Medical Co Ltd
Assigned to SEKISUI MEDICAL CO., LTD. reassignment SEKISUI MEDICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANBA, Yoshimasa, TAKAHASHI, HIROSHI, TAKAHASHI, YUKI, YOSHIDA, TADAAKI
Publication of US20160195522A1 publication Critical patent/US20160195522A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/59—Transmissivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/82—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a precipitate or turbidity
    • G01N21/83—Turbidimetric titration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N2021/1734—Sequential different kinds of measurements; Combining two or more methods
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Definitions

  • the present invention relates to an agglutination immunoassay, more particularly to a particle enhanced agglutination immunoassay involving the measurement of intensity of scattered light and the measurement of absorbance.
  • Particle enhanced agglutination immunoassay is a method for determining an analyte with carrier particles carrying a binding partner or binding partners for the analyte.
  • Immunoassays using such reagents are performed with an automated analyzer, which can obtain results within a short time through a simple operation.
  • the optical measurement performed with such an automated analyzer determines the intensity of scattered light or the absorbance, either of which is independently performed in a single immunoassay.
  • Immunoassays based on the measurement of intensity of scattered light provide high sensitivity, but have a very narrow dynamic range. Due to their narrow dynamic range, repeated sample dilutions and remeasurements are required until the concentration of the analyte become within the measurement range of the assay system. As a result, such immunoassays take a lot of time for reporting the assay results.
  • Patent Document 1 discloses an assay method which aims at providing higher sensitivity and wider dynamic range by performing measurements at different wavelengths.
  • the reagents for particle enhanced agglutination immunoassay disclosed in Patent Documents 2 and 3 aim at providing a wider dynamic range by using two carrier particles of different sizes in combination with antibodies which have different reactivities to an analyte of interest.
  • Patent Document 1 The essence of the technique disclosed in Patent Document 1 is to control the absolute value of the signal: At a low concentration of an analyte, the measurement is performed at a short wavelength which provides a strong signal, and at a high concentration of the analyte, the measurement is performed at a long wavelength which prevents the signal from exceeding the upper limit of detection of the analyzer.
  • the turbidity of a microparticle solution depends on the wavelength, and a signal is weaker at a longer wavelength.
  • Patent Document 1 merely controls the signal intensity for a certain optical change by selecting the wavelength, so that the signal can be detected by the analyzer, and is not expected to have a dramatic improvement effect to compensate the drawbacks of limited accuracy and dynamic range in particle enhanced agglutination immunoassays.
  • the present inventors have conceived to combine measurements of the intensity of scattered light and the absorbance for a single assay in particle enhanced agglutination immunoassay to achieve an assay with increased sensitivity and an expanded dynamic range, and have demonstrated the potential of such an immunoassay.
  • Some conventional analyzers can measure the intensity of scattered light and the absorbance substantially at the same time, as that disclosed in Japanese Patent Application Laid-Open Publication No. 2001-141654, for example. Such analyzers merely aim at practicing the two different analytical methods with a single analyzer: the intensity of scattered light is measured for agglutination immunoassay, and the absorbance is measured for spectrophotometry to determine spectral changes associated with enzymatic or chemical reactions.
  • Conventional documents neither describe nor suggest, and no one has conceived of, a particle enhanced agglutination immunoassay including both measurements in combination in a single assay.
  • a degree of aggregation caused by a reaction between an analyte and carrier particles carrying a binding partner or binding partners for the analyte for a certain time was controlled by selecting main components of a reagent for assay, that is, by selecting the type or amount of the binding partner, or the size of the carrier particles, as described above. Specifically, use of larger particles and a binding partner with higher reactivity results in increased sensitivity, and use of smaller particles and a binding partner with lower reactivity results in a wider dynamic range. Based on the above, persons skilled in the art have concentrated their efforts for increased sensitivity and expanded dynamic range in particle enhanced agglutination immunoassay on design of reagents for assay.
  • An object of the present invention is to provide a simpler particle enhanced agglutination immunoassay with higher sensitivity and wider dynamic range than conventional techniques, by combining measurement of the intensity of scattered light to achieve high sensitivity and measurement of the absorbance under analytical conditions specific for expansion of dynamic range in a single assay.
  • the inventors who have made extensive studies, have arrived at a particle enhanced agglutination immunoassay including both measurement of the intensity of scattered light and measurement of the absorbance in a single assay performed with a reagent which is designed to provide high sensitivity in measurement of the intensity of scattered light but limits a dynamic range.
  • the method includes determining a variation in absorbance between two time points, wherein the time period between the two time points is shorter than the time period for which a variation in intensity of scattered light is determined.
  • the inventors have successfully plotted calibration curves which substantially cover both low and high concentration ranges of analyte in a single assay, and have accomplished a particle enhanced agglutination immunoassay which includes both measurement of the intensity of scattered light and measurement of the absorbance in combination and which achieves high sensitivity and a wide dynamic range.
  • the present invention provides the following aspects:
  • a particle enhanced agglutination immunoassay including the steps of: mixing a sample solution containing an analyte with a solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte to prepare a mixed solution; determining a variation (i) in intensity of light scattered from the mixed solution based on a difference in intensity of scattered light between first and second time points; determining a variation (ii) in absorbance of the mixed solution based on a difference in absorbance between third and fourth time points; and correlating the determined variation (i) in intensity of scattered light and the determined variation (ii) in absorbance with an amount of the analyte present in the sample using a calibration curve plotted based on the variation in intensity of scattered light and a calibration curve plotted based on the variation in absorbance.
  • Aspect [2] The immunoassay according to Aspect [1], wherein the first, second, third, and fourth time points are respectively selected between 0 and 1000 seconds after the start of preparation of the mixed solution.
  • Aspect [3] The immunoassay according to Aspect [1] or [2], wherein the time period which is defined by the third and fourth time points and for which the variation (ii) is determined is shorter than the time period which is defined by the first and second time points and for which the variation (i) is determined.
  • Aspect [4] The immunoassay according to any one of Aspects [1] to [3], wherein the variations (i) and (ii) are determined at the same wavelength.
  • Aspect [6]. The immunoassay according to Aspect [5], wherein the variation (ii) in absorbance is determined at two wavelengths consisting of main and sub-wavelengths which are shorter and longer, respectively, than the wavelength at which the variation (i) in intensity of scattered light is determined.
  • Aspect [7]. The immunoassay according to any one of Aspects [1] to [6], wherein the variations (i) and (ii) are determined at a wavelength within the range of from 550 to 900 nm.
  • the present invention provides a particle enhanced agglutination immunoassay which provides higher sensitivity and a wider dynamic range than conventional assays and which reduces efforts and costs required for designing reagents for use in particle enhanced agglutination immunoassay.
  • FIG. 1 is a chart for PSA concentration-dependent variations in light quantity observed under conditions of measurement of the intensity of scattered light, measurement of the absorbances in the present invention, and measurement of the absorbance in a conventional method as a comparative example.
  • FIG. 2A is a chart for the level of decrease in measurements (under conditions of measurement of absorbance 1) due to the prozone effect observed in immunoassays of samples containing ultra-high concentrations of PSA under various conditions of measurements of absorbance in the present invention.
  • FIG. 2B is a chart for the level of decrease in measurements (under the condition of measurement of absorbance 2) due to the prozone effect observed in immunoassays of samples containing ultra-high concentrations of PSA under various conditions of measurements of absorbance in the present invention.
  • FIG. 3 is a chart for correlation observed in an immunoassays of PSA-positive samples according to the particle enhanced agglutination immunoassay of the present invention.
  • the particle enhanced agglutination immunoassay includes the steps of:
  • the method including such steps according to the embodiment of the present invention allows to plot calibration curves which substantially cover both low and high concentration ranges of analyte, and achieves high sensitivity and a wide dynamic range in particle enhanced agglutination immunoassay.
  • the first, second, third, and fourth time points are respectively selected between 0 and 1000 seconds after the start of preparation of the mixed solution. Selecting the time points within this range provides both desired sensitivity and dynamic range for the immunoassay, and also allows a high degree of freedom in design of a reagent for assay.
  • the variation (i) in intensity of scattered light and the variation (ii) in absorbance are preferably determined at the same wavelength, and preferably within the range of from 550 to 900 nm.
  • single assay refers to a series of reactions and measurements performed in a single reaction cuvette.
  • a single assay in an immunoassay performed with an automated analyzer includes the following steps which are carried out in a single reaction cuvette: mixing a first reagent solution with a sample; subsequently adding and mixing a second reagent solution (i.e. solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte); determining a variation in intensity of scattered light; and determining a variation in absorbance.
  • a second reagent solution i.e. solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte
  • sample solution containing an analyte includes a sample solution mixed or diluted with a first reagent solution (buffer solution) as described above.
  • the term “intensity of scattered light” is also interchangeably referred to as “scattered light intensity”.
  • the insoluble carrier used in the particle enhanced agglutination immunoassay of the present invention may be any material that is applicable as a component of a reagent for assay.
  • the insoluble carrier include latex, colloidal metal, silica, and carbon.
  • the insoluble carrier particles may have any average particle size appropriately selected from within the range of from 0.05 to 1 ⁇ m.
  • the reagent for use in the particle enhanced agglutination immunoassay of the present invention contains carrier particles having an average particle size which is smaller than the wavelength of the light irradiated during the measurement of the intensity of scattered light with a difference of 250 to 450 nm, specifically 300 to 450 nm.
  • the insoluble carrier particles preferably have an average particle size of 250 nm to 400 nm.
  • the average particle size of the insoluble carrier particles can be determined by a general method with a particle analyzer or a transmission electron microscope, for example.
  • the particle enhanced agglutination immunoassay of the present invention is applicable for determination of various types of biological samples, including, but not limited to, body fluids such as blood, serum, plasma, and urine, for example.
  • the analyte to be determined in the particle enhanced agglutination immunoassay of the present invention can be any molecule that can be theoretically determined by particle enhanced agglutination immunoassay, such as proteins, peptides, amino acids, lipids, sugars, nucleic acids, and haptens.
  • analyte examples include CRP (C-reactive protein), Lp(a) (lipoprotein (a)), MMP3 (matrix metalloproteinase 3), anti-CCP (anti-cyclic citrullinated peptide) antibody, antiphospholipid antibody, anti-syphilis antigen antibody, RPR, type IV collagen, PSA, AFP, CEA, BNP (brain natriuretic peptide), NT-proBNP, insulin, microalbumin, cystatin C, RF (rheumatoid factor), CA-RF, KL-6, PIVKA-II, FDP, D-dimer, SF (soluble fibrin), TAT (thrombin-antithrombin III complex), PIC, PAI, factor XIII, pepsinogen I, pepsinogen II, phenytoin, phenobarbital, carbamazepine, valproic acid, and theophylline.
  • CRP C-reactive protein
  • the binding partner used in the particle enhanced agglutination immunoassay according to the present invention may be any material that binds to an analyte.
  • the binding partner include proteins, peptides, amino acids, lipids, sugars, nucleic acids, and haptens.
  • Antibodies and antigens are typically used as binding partner, in view of their specificity and affinity.
  • the binding partner may have any molecular weight, and may be either naturally occurring or synthesized.
  • the reagent for use in the particle enhanced agglutination immunoassay of the present invention may have any composition. If the reagent is for use with an automated analyzer generally used in the field of clinical laboratory tests, the reagent is typically composed of two solutions: a first reagent solution (R1) containing a buffer solution; and a second reagent solution (R2) containing carrier particles which carry a binding partner or binding partners for the analyte.
  • R1 a first reagent solution
  • R2 second reagent solution
  • the reagent for assay according to the present invention may also contain a component for buffering the ionic strength or osmotic pressure, for example, of the sample.
  • a component for buffering the ionic strength or osmotic pressure for example, of the sample.
  • examples of such a component include acetic acid, citric acid, phosphoric acid, Tris, glycine, boric acid, carbonic acid, and Good's buffer, and sodium salts, potassium salts, and calcium salts thereof.
  • the reagent for assay according to the present invention may also contain a component for enhancing agglutination. Examples of such a component include polymers such as poly(ethylene glycol), poly(vinyl pyrrolidone), and phospholipid polymer.
  • the reagent for assay according to the present invention may also contain one or more components generally used for controlling agglutination.
  • a component include macromolecular substances, proteins, amino acids, sugars, metal salts, surfactants, reducing substances, and chaotropic substances.
  • the reagent for assay according to the present invention may also contain an antifoaming substance.
  • the particle enhanced agglutination immunoassay of the present invention is suitable to be performed with an automated analyzer.
  • Use of an automated analyzer reduces the total reaction time required for the immunoassay to 10 minutes or less, and allows a quick and simple determination.
  • the automated analyzer preferably can measure the intensity of scattered light and the absorbance substantially at the same time, as is disclosed in Japanese Patent Application Laid-Open Publication No. 2013-64705.
  • the forward scattering angle in the measurement of intensity of scattered light of the present invention may have any value, and is preferably within the range of 15 to 35 degrees, more preferably within the range of 20 to 30 degrees.
  • a scattering angle within such a range prevents excessive influences by transmitted light on a light receiver for detection of the scattered light, and is advantageous for its ability to receive the scattered light.
  • the intensity of scattered light according to the present invention may be measured with any light source, and the light used for the measurement may have any wavelength.
  • the light preferably has a wavelength within the visible light region, which is suitable for particle enhanced agglutination immunoassay.
  • the wavelength is preferably within the range of 650 to 750 nm.
  • the variation in the intensity of scattered light may be determined between any two predetermined time points. In general, higher sensitivity is provided if the time period between the two time points is longer.
  • the automated analyzer described above can individually determine a variation in intensity of scattered light and a variation in absorbance for a time period defined by any two time points selected between 0 and at most 1000 seconds after mixing of a sample solution containing the analyte with a solution containing insoluble carrier particles which carry a binding partner or binding partners for the analyte. If the individual variations in the intensity of scattered light and the absorbance are determined for time periods defined by two time points selected between 0 and 300 seconds after the mixing, the assay can reduce the total time of single assay (for a single sample) with the first and second reagent solutions to 10 minutes or less, and provides the benefit of the highest sample analysis speed of various commercially available automated analyzers.
  • the absorbance in the present invention may be measured at any wavelength, and a suitable wavelength is within a range of ⁇ 25% of a wavelength at which the variation in intensity of scattered light is determined, preferably within a range of 550 to 900 nm, more preferably within a range of 570 to 800 nm.
  • the wavelengths for the measurements of the absorbance and the intensity of scattered light may be either the same or different.
  • the absorbance in the present invention may be measured either at a single wavelength or at two wavelengths consisting of a main or shorter wavelength and a sub or longer wavelength than the wavelength used in the measurement of the intensity of scattered light, within the aforementioned ranges.
  • the main and sub wavelengths for the measurement of the absorbance may be set within ranges of from 550 to 699 nm and from 701 to 900 nm, respectively.
  • the variation in the absorbance may be determined for a time period between two measurements at any two time points, and is suitably determined for a shorter period than, preferably a half or less of, the time period for which the variation in the intensity of scattered light is determined.
  • the variation in the absorbance may be preferably determined for a time period of a third or less of the time period for which the variation in the intensity of scattered light is determined. For example, if the variation in the intensity of scattered light is determined for a time period of 300 seconds, the variation in absorbance is preferably determined for a time period of 150 seconds or less, more preferably 100 seconds or less in some cases.
  • the measurement is preferably started just after mixing the sample solution containing the analyte with the solution containing insoluble carrier particles carrying a binding partner or binding partners for the analyte.
  • variations in values of light quantity (intensity of scattered light and absorbance) in the present invention may be determined by any method applicable to particle enhanced agglutination immunoassay, including calculation of difference, ratio, and a value per unit time for the two time points.
  • a sample containing a known concentration of analyte is analyzed for intensity of scattered light and absorbance to plot individual calibration curves based on the measurements.
  • the concentration is determined based on the calibration curve plotted based on the measurement of the intensity of scattered light, such that high sensitivity is achieved
  • the concentration is determined based on the calibration curve plotted based on the measurement of the absorbance, such that a wide dynamic range is achieved.
  • the determination based on the absorbance provides a wide dynamic range, and allows to plot a calibration curve which covers a wider concentration range.
  • sensitivity refers to a minimum measurable amount of an analyte. In general, larger variations in light quantity associated with the amount of light means higher sensitivity.
  • the high sensitivity is indicated by the high accuracy and repeatability of the measurements for the amount of the analyte at a low concentration.
  • dynamic range refers to a range between the lowest and highest measurable amounts of an analyte.
  • the dynamic range represents a range within which variations in light quantity proportional to the analyte concentration can be detected.
  • the sensitivity and dynamic range of a particle enhanced agglutination immunoassay are dependent on insoluble carrier particles which are contained in a reagent used for the assay and which carry a binding partner or binding partners to the analyte. These two characteristics are in a trade-off relation, as described above.
  • Step (2) Each mixed solution in Step (2) was subjected to centrifugation to separate the supernatant, and the supernatant was then suspended in a 5 mM MOPS buffer solution (having a pH of 7.0). The resulting solution was adjusted such that the absorbance at a wavelength of 600 nm was 1.5 Abs/mL. These two solutions were then mixed in equivalent amounts to prepare a second reagent solution (R2) (solution of antibody-immobilized latex).
  • R2 solution of antibody-immobilized latex
  • a first reagent solution was prepared as 30 mM Tris-HCl buffer solution (having a pH of 8.5) containing 1 M potassium chloride and 0.1% BSA.
  • Both the intensity of scattered light and the absorbance were measured in a single assay with the automated analyzer disclosed in the Japanese Patent Application Laid-Open Publication No. 2013-64705.
  • the conditions of the measurement of the intensity of scattered light were established such that the wavelength of irradiated light was 700 nm and the scattering angle was 30 degrees.
  • the conditions of the measurement of the absorbance were established such that the measurement was performed at two wavelengths consisting of the main wavelength of 570 nm and the sub-wavelength of 800 nm.
  • 100 ⁇ L of R1 was added, and the mixture was stirred and then subjected to incubation for about 300 seconds at 37° C.
  • the measured values of the intensity of scattered light and the absorbance were respectively calibrated by spline with a PSA calibrator (available from SEKISUI MEDICAL CO., LTD.) to plot respective calibration curves.
  • the PSA concentrations in the sample were determined based on the respective calibration curves.
  • the concentration range of the calibration curves was selected for each measurement depending on the dynamic range under each measurement condition.
  • the variations in light quantity were determined by the immunoassay according to the present invention based on the intensity of scattered light and the absorbance. The variations were determined for a time period of 270 seconds from about 30 seconds after the addition of R2, for which the highest sensitivity is supposed in determination of PSA according to the Example. Samples containing PSA at different two concentrations (0.4 ng/mL and 1 ng/mL, respectively) were serially analyzed ten times, and the repeatability was confirmed for the measurement of the intensity of scattered light and the measurement of the absorbance (see Table 1). While the clinical cut-off value for PSA is 4 ng/mL, the measurement of the intensity of scattered light provided high sensitivity and showed high accuracy and repeatability even at a concentration of 1 ng/mL or lower.
  • Measurements were performed under the following conditions with different time periods for determination: the intensity of scattered light was measured for the time period between about 30 seconds after the addition of R2 (the first time point) and 270 seconds after the first time period (the second time period); the absorbance 1 was measured for the time period between about 30 seconds after the addition of R2 (the third time point (a)) and about 90 seconds after the third time point (a) (the fourth time point (a)) (condition 1 of the present invention); the absorbance 2 was measured for the time period between about 15 seconds after the addition of R2 (the third time point (b)) and about 90 seconds after the third time point (b) (the fourth time point (b)) (condition 2 of the present invention); and the absorbance 3 was measured for the time period between about 30 seconds after the addition of R2 (the third time point of the comparative example) and 270 seconds after the third time point of the comparative example (the fourth time point of the comparative example) (conventional conditions (comparative example)). Dynamic ranges of determination based on the respective measurements
  • the determination based on the measurements of the intensity of scattered light shows a narrow dynamic range, with the peak at the PSA concentration of 25 ng/mL. At a concentration higher than 25 ng/mL, the variation in the intensity of scattered light decreases gradually.
  • the determination based on the measurements of the absorbance 3 under conventional conditions (comparative example) shows a similar dynamic range, but with a more modest decrease in the variation in light quantity at a high concentration range.
  • the determination based on the measurements of absorbances 1 and 2 under the conditions of the present invention shows concentration-dependent increase in light quantity even in the high concentration range. The results thus demonstrate that the present invention provides wide dynamic ranges.
  • samples containing PSA at concentrations exceeding the range of from 100 ng/mL to 300 ng/mL were analyzed under the conditions of measurements for absorbances 1 and 2 according to the present invention, to observe the prozone effect (see FIG. 2A and FIG. 2B ).
  • the prozone effect refers to a decrease in apparent measurements observed in particle enhanced agglutination immunoassay due to an excessive amount of antigen, and is a serious problem in clinical laboratory tests, because it can cause false-negative results and consequent misdiagnosis.
  • the determination under condition 2 showed a wider dynamic range with a more modest decrease in measurements due to the prozone effect.
  • the results suggest that the practical upper limits of measurement under conditions of measurements for absorbances 1 and 2 are approximately 50 ng/mL (see FIG. 2A ) and 100 ng/mL (see FIG. 2B ), respectively, and demonstrate that the condition of measurement for the absorbance 2 allows a measurement range in a higher concentration range.
  • PSA-positive samples containing known concentrations of PSA were analyzed by the particle enhanced agglutination immunoassay according to the present invention, to confirm correlation based on measurements under the condition of measurement for the intensity of scattered light ( ⁇ ) and measurements under the condition of measurement for the absorbance 2 ( ⁇ ), respectively, in a low concentration range (up to 10 ng/mL) and a high concentration range (over 10.1 ng/mL) (see FIG. 3 ).
  • results show high correlation and indicates that the present invention provides a particle enhanced agglutination immunoassay with high sensitivity and a wide dynamic range.
  • the present invention employs measurements of intensity of scattered light and absorbance in combination for a single assay.
  • the present invention thus provides a particle enhanced agglutination immunoassay which provides higher sensitivity and a wider dynamic range than conventional assays and which reduces efforts and costs required for designing reagents for use in particle enhanced agglutination immunoassay.
US14/894,207 2013-05-31 2014-06-02 Method of agglutination immunoassay Abandoned US20160195522A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013115756 2013-05-31
JP2013-115756 2013-05-31
PCT/JP2014/064659 WO2014192963A1 (fr) 2013-05-31 2014-06-02 Procédé d'immuno-essai à agglutination

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/064659 A-371-Of-International WO2014192963A1 (fr) 2013-05-31 2014-06-02 Procédé d'immuno-essai à agglutination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/256,732 Continuation US11536717B2 (en) 2013-05-31 2019-01-24 Method of agglutination immunoassay

Publications (1)

Publication Number Publication Date
US20160195522A1 true US20160195522A1 (en) 2016-07-07

Family

ID=51988979

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/894,207 Abandoned US20160195522A1 (en) 2013-05-31 2014-06-02 Method of agglutination immunoassay
US16/256,732 Active 2034-09-13 US11536717B2 (en) 2013-05-31 2019-01-24 Method of agglutination immunoassay

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/256,732 Active 2034-09-13 US11536717B2 (en) 2013-05-31 2019-01-24 Method of agglutination immunoassay

Country Status (6)

Country Link
US (2) US20160195522A1 (fr)
EP (2) EP3418724B1 (fr)
JP (2) JPWO2014192963A1 (fr)
KR (1) KR102302678B1 (fr)
CN (2) CN110068678A (fr)
WO (1) WO2014192963A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11237179B2 (en) 2017-10-31 2022-02-01 Canon Medical Systems Corporation Calibration curve generating method and automatic analyzing apparatus
US11692929B2 (en) 2016-01-22 2023-07-04 Hitachi High-Tech Corporation Automatic analyzer and standard solution for evaluating scattered light measurement optical system thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5920409B2 (ja) * 2014-06-18 2016-05-18 栗田工業株式会社 凝集モニタリング装置、凝集モニタリング方法および凝集システム
CN105974105A (zh) * 2016-05-16 2016-09-28 河北艾驰生物科技有限公司 基质金属蛋白酶-3（mmp3）检测试剂盒
CN113281284A (zh) * 2016-07-19 2021-08-20 株式会社日立高新技术 自动分析装置及自动分析方法
KR20190042050A (ko) * 2016-08-31 2019-04-23 세키스이가가쿠 고교가부시키가이샤 애널라이트 농도 측정법, 응집 형광 재료 함유 입자 및 검사 디바이스
CN110114677B (zh) * 2016-12-15 2023-06-20 株式会社堀场制作所 使用了免疫凝聚反应的浓度测定中的受试物质浓度的适当性的判定方法及具有用于该判定方法的处理部的试样分析装置
CN107102153A (zh) * 2017-05-18 2017-08-29 天津市宝坻区人民医院 血清中脂蛋白a先后双试剂测定方法
CN107748254A (zh) * 2017-09-30 2018-03-02 安徽伊普诺康生物技术股份有限公司 一种n‑端脑利钠肽前体检测试剂盒及其应用
CN107741492A (zh) * 2017-09-30 2018-02-27 安徽伊普诺康生物技术股份有限公司 一种包被有n‑端脑利钠肽前体抗体的胶乳微球的制备方法
CN107727866A (zh) * 2017-09-30 2018-02-23 安徽伊普诺康生物技术股份有限公司 一种n‑端脑利钠肽前体检测试剂盒的制备方法
CN109633148B (zh) * 2018-12-27 2021-08-06 恩碧乐(杭州)生物科技有限公司 Kl-6检测乳胶凝集试剂
CN109738348A (zh) * 2019-01-28 2019-05-10 大连医科大学 基于颗粒计数的免疫凝集反应强度定量分析方法
KR20220159382A (ko) 2020-03-30 2022-12-02 덴카 주식회사 라텍스 응집법에 의한 목적 물질의 측정 방법 및 그 시약
CN112485438B (zh) * 2020-11-10 2022-07-22 深圳市科曼医疗设备有限公司 一种特定蛋白反应检测方法和装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168784A1 (en) * 1998-07-23 2002-11-14 Erling Sundrehagen Agglutination assays
JP2008008794A (ja) * 2006-06-29 2008-01-17 Olympus Corp 分析装置
JP2008298505A (ja) * 2007-05-30 2008-12-11 Jsr Corp 標的物質の検出方法、混合粒子、および標的物質の検出試薬
CN101907628A (zh) * 2009-06-08 2010-12-08 武汉中太生物技术有限公司 全血中c反应蛋白含量测定试剂盒及其测定方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06186156A (ja) * 1992-10-21 1994-07-08 Toa Medical Electronics Co Ltd 粒子分析装置
JPH0843393A (ja) * 1994-07-29 1996-02-16 Shima Kenkyusho:Kk 免疫学的測定方法及び分析装置
JP3375203B2 (ja) * 1994-08-08 2003-02-10 シスメックス株式会社 細胞分析装置
JPH1026622A (ja) * 1996-05-10 1998-01-27 Sekisui Chem Co Ltd ヒトα−フェトプロテインの定量法および測定キット
JP3249919B2 (ja) * 1996-07-30 2002-01-28 株式会社堀場製作所 免疫測定方法
CA2244326C (fr) 1997-08-11 2006-03-28 Shinichi Eda Essai d'agglutination par diffusion de la lumiere, ameliore par des microparticules; reactifs microparticulaires utiles a cette fin
WO2000006991A2 (fr) * 1998-07-27 2000-02-10 Ljl Biosystems, Inc. Appareil et procedes de mesures spectroscopiques
DE19948587A1 (de) 1999-10-08 2001-04-12 Dade Behring Marburg Gmbh Spektralphotometrische und nephelometrische Detektionseinheit
EP1096248B1 (fr) 1999-10-28 2007-01-10 Matsushita Electric Industrial Co., Ltd. Méthode pour déterminer la concentration d'une solution
JP3694449B2 (ja) 1999-10-28 2005-09-14 松下電器産業株式会社 溶液濃度計測方法および溶液濃度計測装置
JP2001249134A (ja) 1999-12-28 2001-09-14 Matsushita Electric Ind Co Ltd タンパク質濃度計測用試薬、これを用いたタンパク質濃度計測方法および尿検査方法
JP3513075B2 (ja) 2000-04-05 2004-03-31 デンカ生研株式会社 免疫測定法及びそのための試薬
JP3779885B2 (ja) * 2001-03-26 2006-05-31 株式会社堀場製作所 免疫測定方法
WO2003005031A1 (fr) * 2001-07-02 2003-01-16 Sekisui Chemical Co., Ltd. Latex a particules supports pour reactif d'essai, et reactif d'essai
JP4299597B2 (ja) * 2002-07-29 2009-07-22 シスメックス株式会社 血液分析装置及び方法
EP1496361B1 (fr) * 2003-07-07 2006-10-25 Matsushita Electric Industrial Co., Ltd. Assay et système immunologique, utilisant une transformation Fourier, pour évaluer la survenue des phénomènes de zones.
US20070212678A1 (en) * 2004-04-23 2007-09-13 Amgen Inc. Method And Apparatus For Predicting Aggregation Kinetics Of A Biologically Active Material
CN1295494C (zh) * 2004-07-04 2007-01-17 华中科技大学 集成化微型光学分析仪
WO2009117510A2 (fr) * 2008-03-20 2009-09-24 Abaxis, Inc. Analyses à plusieurs longueurs d'onde de tests de liaison spécifiques sol-particules
US8507282B2 (en) * 2009-03-13 2013-08-13 Kowa Company, Ltd. Method for measuring physiologically active substance of biological origin, program for implementing the same, and apparatus for measuring physiologically active substance of biological origin
EP2511707B1 (fr) * 2009-12-10 2017-02-01 Sysmex Corporation Procédé de détection de peptide basique et réactif pour la détection de peptide basique
CN101819202B (zh) * 2010-05-06 2012-12-26 上海太阳生物技术有限公司 D-二聚体(D-Dimer)测定试剂盒(胶乳免疫比浊法)
JP5786188B2 (ja) 2010-06-08 2015-09-30 株式会社シノテスト 試料中のｃ反応性蛋白質の測定試薬、測定方法及び測定範囲の拡大方法
JP2012078181A (ja) 2010-09-30 2012-04-19 Gs Yuasa Corp 充放電回路、二次電池の劣化診断装置、加温装置および電池パック
JP5822534B2 (ja) 2011-05-13 2015-11-24 株式会社日立ハイテクノロジーズ 自動分析装置
CN202196011U (zh) * 2011-07-29 2012-04-18 肖才斌 一种便携式多功能分析仪
JP5740264B2 (ja) 2011-09-20 2015-06-24 株式会社日立ハイテクノロジーズ 自動分析装置及び分析方法
JP5593291B2 (ja) 2011-09-21 2014-09-17 株式会社日立ハイテクノロジーズ 自動分析装置
KR20190042050A (ko) * 2016-08-31 2019-04-23 세키스이가가쿠 고교가부시키가이샤 애널라이트 농도 측정법, 응집 형광 재료 함유 입자 및 검사 디바이스

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168784A1 (en) * 1998-07-23 2002-11-14 Erling Sundrehagen Agglutination assays
JP2008008794A (ja) * 2006-06-29 2008-01-17 Olympus Corp 分析装置
JP2008298505A (ja) * 2007-05-30 2008-12-11 Jsr Corp 標的物質の検出方法、混合粒子、および標的物質の検出試薬
CN101907628A (zh) * 2009-06-08 2010-12-08 武汉中太生物技术有限公司 全血中c反应蛋白含量测定试剂盒及其测定方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Machine translation of CN 101907628 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11692929B2 (en) 2016-01-22 2023-07-04 Hitachi High-Tech Corporation Automatic analyzer and standard solution for evaluating scattered light measurement optical system thereof
US11237179B2 (en) 2017-10-31 2022-02-01 Canon Medical Systems Corporation Calibration curve generating method and automatic analyzing apparatus

Also Published As

Publication number Publication date
KR102302678B1 (ko) 2021-09-27
JPWO2014192963A1 (ja) 2017-02-23
EP3006922A4 (fr) 2017-02-15
JP2019060891A (ja) 2019-04-18
CN110068678A (zh) 2019-07-30
JP6675104B2 (ja) 2020-04-01
EP3006922B1 (fr) 2018-08-01
EP3418724B1 (fr) 2020-10-28
US11536717B2 (en) 2022-12-27
WO2014192963A1 (fr) 2014-12-04
US20190154674A1 (en) 2019-05-23
KR20160014007A (ko) 2016-02-05
EP3418724A1 (fr) 2018-12-26
EP3006922A1 (fr) 2016-04-13
CN105431728A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
US11536717B2 (en) Method of agglutination immunoassay
JP6750066B2 (ja) ビタミンｄ結合タンパク質からビタミンｄを解離するための溶液、その関連検出法及び使用
EP2085782B1 (fr) Procédé d'essai immunologique d'un composant à mesurer
US20110263042A1 (en) Assay method for antibodies against cyclic citrullinated peptide
US20220113322A1 (en) Rapid measurement of total vitamin d in blood
EP1801590B1 (fr) Procédé d'analyse d'antigène et réactif correspondant
CN102395885A (zh) 均相凝集免疫测定方法和用于这种方法的试剂盒
WO2014051144A1 (fr) Procédé de détection immunologique et réactif pour détection immunologique
EP2554991B1 (fr) Procédé pour réduire l'interférence due à un composant extérieur au système de dosage immunologique utilisant l'agglutination de latex
Yamamoto et al. Automated homogeneous liposome-based assay system for total complement activity
Tongdee et al. One-incubation one-hour multiplex ELISA enabled by aqueous two-phase systems
EP2980586B1 (fr) Procédé de test de l'insuline
CN109142753A (zh) 鳞状上皮细胞癌抗原化学发光免疫检测试剂盒及其制备方法
CN107860930A (zh) 一种心型脂肪酸结合蛋白的免疫比浊检测试剂和方法
US20190056388A1 (en) Improved assay
Moreau et al. Development of the VIDAS® 25 OH Vitamin D Total assay
US20160169884A1 (en) Device and method for biological analyses
Purice et al. Comparison between immunometric methods for the determination of FSH, LH, TSH and PRL hormones in CSF
Wosnitza et al. Quantitation of IgG using PAIA assays on Cellavista and NyONE imagers
CN111868526A (zh) 减少免疫测定中的干扰
Lautenschlager et al. A comparison of AlphaLISA and TR-FRET homogeneous immunoassays in serum-containing samples
Napodano et al. PERFORMANCE AND SENSITIVITY OF SCREENING ELECROPHRETIC METHODS FOR THE RESEARCH OF BENCE JONES PROTEIN
Tyagarajan et al. A Novel Bead-based IgG Quantitation Assay on the Guava Microcapillary Platform

Legal Events

Date Code Title Description
AS Assignment

Owner name: SEKISUI MEDICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKAHASHI, HIROSHI;YOSHIDA, TADAAKI;BANBA, YOSHIMASA;AND OTHERS;REEL/FRAME:037222/0519

Effective date: 20151124

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION